Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 14/20 | 0.32 |
| ▸ | KMO | O15229 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3625929 | 0.81 | CHRM1 (0.34) | — | |
| SCHEMBL16118505 | 0.68 | ALDH1A1 (0.46) | — | |
| SCHEMBL5164869 | 0.68 | ALDH1A1 (0.46) | — | |
| SCHEMBL28626450 | 0.65 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL16118554 | 0.65 | HSD11B1 (0.44) | IDH1SLC6A2SLC6A4 | |
| SCHEMBL6824596 | 0.63 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11191009 | 0.63 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL21494388 | 0.63 | ADRA2A (0.47) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13036344 | 0.62 | CHRM2 (0.39) | IDH1 | |
| SCHEMBL13036339 | 0.62 | CHRM2 (0.39) | IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069385-A1 | Antidiabetic Oxazolidinediones and Thiazolidinediones | MERCK SHARP & DOHME CORP. | 2009-03-12 | — | — | US | disclosed |
| US-20090069385-A1 | Antidiabetic Oxazolidinediones and Thiazolidinediones | MERCK SHARP & DOHME CORP. | 2009-03-12 | — | — | US | disclosed |
| EP-1909789-A2 | ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES | Merck & Co., Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1909789-A2 | ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES | Merck & Co., Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007018956-A3 | ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES | MERCK & CO INC (US) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007018956-A2 | ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES | MERCK & CO., INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007018956-A2 | ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES | MERCK & CO., INC. (US) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069385-A1 | Antidiabetic Oxazolidinediones and Thiazolidinediones | PPARD, PPARA, PPARG | IDH1 1126/4885KMO 2232/4885SLC6A2 4364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.